Login Open account
International
By using our website you agree to our use of cookies in accordance with our cookie policy.
Okay
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider.
Show more
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs, FX or any of our other products work and whether you can afford to take the high risk of losing your money.
Show less
Strats_Blue-I
SaxoStrats

Market Call Podcast

John Hardy
Head of FX Strategy
Read More
NewYorkM
Macro

U.S. Jobless Claims: Another good metric but…

Christopher Dembik
U.S. initial jobless claims and continuing claims are down again - which is rather positive considering the reintroduction of new business restrictions in states due to rising Covid-19 counts. However, the market is not really impressed. (1) Continuing claims remain still very elevated, at 5.500k versus 1,700k before the outbreak. (2) Investors are all eyeing at tomorrow's government jobs report to have a better picture of the real state of the labor market.
Commodities

Food inflation ran wild in November

Ole Hansen
Global food prices, led by edible oils, rose strongly in November with the UN FAO Food Price index hitting a six-year high.
Equities

Record equity valuations, container rates, Snowflake earnings

Peter Garnry
Equity valuations have hit the highest levels since the 1960s, but should that scare investors away from equities? We also take a look at the surging container rates and food prices indicating inflationary pressures. Finally, we comment on yesterday's Snowflake earnings.
COT Update: IMM currency futures
Forex

FX Update: USD breakdown has unfolded, requires constant equity fuel

John Hardy
A US dollar breakdown has unfolded over the last couple of sessions, a notable development as major chart levels in a number of USD pairs have given way, but the move seems to require constant fuel from risk sentiment. Elsewhere, some of the usual correlations are misbehaving slightly and sterling is in its own world on fresh Brexit uncertainty.
Podcast

Podcast: Is the US equity market primed for a crash?

Saxo Market Call
Today we highlight the incredible surge in equity call option trading in the US this year and especially in recent weeks and ponder whether the underlying market structure risks a significant market dislocation event on any exogenous shock - i.e., a proper crash. We also highlight important equity, commodity and equity stories while encouraging everyone to keep an eye on US yields as a potential gamechanger if yields continue to rise. Today with Peter Garnry on equities, Ole Hansen on commodities and John J. Hardy hosting and on FX.
Cryptocurrencies

Initial stage of Ethereum 2.0 is up and running

Anders Nysteen
The initial stage of the Ethereum 2.0 upgrade has been launched, providing the first step for being able to process more transactions in a more secure and sustainable way. We provide a brief status two days after the launch.
Macro

Market Quick Take - December 3, 2020

John Hardy
Markets were buffeted yesterday and overnight by both good news and bad, including in the latter column a weak November private payrolls survey in the US and its worst daily death tool ever in the Covid-19 pandemic. On the positive side and taking the US to a marginal new high daily close for the cycle, signs point to the US Congress finally moving toward agreement on a stimulus deal.
Macro

COVID-19 Vaccine: What is the timeline ?

Christopher Dembik
There are good reasons for investors to wear rose-colored glasses right now. While economic risks remain elevated due to the wave of bankruptcies that is in sight, market optimism is rightly fueled by positive vaccine news and expectations of further monetary stimulus from the Federal Reserve and the European Central Bank as early as this month. With the United Kingdom being the first country to grant emergency approval to Pfizer's coronavirus vaccine, we publish today an update on a timeline for when a vaccine might be available for the rest of the world.
Load more

Disclaimer

 The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)
Full disclaimer (https://www.home.saxo/legal/saxoselect-disclaimer/disclaimer)

Democratising trading
and investment for
more than 25 years.

International International

Saxo Bank A/S (Headquarters)
Philip Heymans Alle 15
2900 Hellerup
Denmark

Contact Saxo

Products & pricing

Platforms & services

General

Across

Trade responsibly
All trading carries risk. Read more. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more

This website can be accessed worldwide however the information on the website is related to Saxo Bank A/S and is not specific to any entity of Saxo Bank Group. All clients will directly engage with Saxo Bank A/S and all client agreements will be entered into with Saxo Bank A/S and thus governed by Danish Law.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.